Pharmaceutical Product Monograph: Cytarabine Injection (100 mg, 500 mg, 1 g)
In the pharmaceutical industry, Cytarabine (also known as Ara-C) is an antimetabolite and a Pyrimidine Nucleoside Analog. As a pharmacist and manufacturer, I view this molecule as a “DNA Synthesis Saboteur”—it is technically designed to mimic the natural building blocks of DNA, effectively tricking rapidly dividing cancer cells into incorporating it into their genetic code, which then leads to cell death.
At your WHO-GMP facility in Mumbai, Cytarabine is a high-impact Oncology SKU. It is the backbone of “Induction Therapy” for acute leukemias, where the goal is to clear the bone marrow of malignant cells rapidly.
Therapeutic Profile: Primary Indications
Cytarabine is primarily used for hematological malignancies (blood cancers) and is less effective against solid tumors.
| Indication | Clinical Context | Technical Rationale |
| Acute Myeloid Leukemia (AML) | Induction Therapy | Gold Standard: Used in the “7+3” regimen (7 days of Cytarabine + 3 days of Anthracycline) to induce remission. |
| Acute Lymphocytic Leukemia (ALL) | Remission Induction | Used in both pediatric and adult protocols to target malignant lymphoblasts. |
| Chronic Myeloid Leukemia (CML) | Blast Crisis | Used when the disease transitions into an acute, aggressive phase. |
| Non-Hodgkin’s Lymphoma (NHL) | Salvage Therapy | Used in high-dose protocols for refractory or relapsed lymphoma. |
| Meningeal Leukemia | Intrathecal Use | Injected directly into the spinal fluid to treat or prevent cancer spread to the central nervous system. |
Mechanism: S-Phase Specific Inhibition
Cytarabine is a cell-cycle-specific agent, meaning it only kills cells when they are actively trying to replicate their DNA (the S-phase).
Activation: Once inside the cell, Cytarabine is converted into its active form, Cytarabine Triphosphate (Ara-CTP).
DNA Polymerase Competition: Ara-CTP competes with the natural base (dCTP) for the enzyme DNA Polymerase.
Chain Termination: When the enzyme picks up Cytarabine instead of the natural base, DNA strand elongation is blocked.
Apoptosis: The cell detects the “broken” DNA and triggers programmed cell death (Apoptosis).
The Pharmacist’s “Technical Warning”
The “Cytarabine Syndrome”: As a pharmacist, I must warn of a specific reaction occurring 6–12 hours after administration, characterized by fever, bone pain, chest pain, and rash. It is technically managed with corticosteroids.
Neurotoxicity: High-dose Cytarabine can cause Cerebellar Toxicity (slurred speech, loss of balance). Patients must be tested for “Finger-to-Nose” coordination before every dose.
Ocular Toxicity: High doses are excreted in tears and can cause severe conjunctivitis. Steroid eye drops are a technical requirement throughout treatment.
Myelosuppression: This drug causes profound bone marrow suppression. Patients will require frequent blood transfusions and isolation to prevent infections.The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Intrathecal Safety” USP: On your digital platforms, emphasize that your Cytarabine is Preservative-Free. This is a critical technical requirement for spinal (intrathecal) injections, as preservatives like Benzyl Alcohol are neurotoxic.
The “Oncology Portfolio” Bundle: For international B2B tenders, market Cytarabine alongside Daunorubicin or Idarubicin. Offering the complete “Induction Kit” is a major procurement advantage for government health ministries.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Cytarabine 100 mg and 500 mg vials to support your registration in international B2B oncology tenders.